BACKGROUND: The longevity of a stentless valve in a younger population (20-60 years old) is unknown. METHODS: From 1992 to 2015, 1947 patients underwent aortic valve/root replacement for aortic stenosis, insufficiency, root aneurysm, or aortic dissection with stentless bioprostheses (median size, 26 mm). At operation 105 patients were <40 years old, 528 were 40 to 59, 860 were 60 to 74, and 454 were ≥75 years. The data were obtained through chart review, administered surveys, and the National Death Index. RESULTS: The 30-day mortality rate was 2.6%. During follow-up 807 patients (41%) died before reoperation, 993 (51%) were alive without reoperations because of deterioration, and 113 patients (5.8%) underwent reoperation for structural valve deterioration. After adjusting death and reoperation for non-structural valve deterioration causes as competing risks, the cumulative incidence of reoperation was significantly different between the younger groups (<40, 40-59) and the older groups (60-74, ≥75; P < .0001) but not inside the younger (<40 vs 40-59) or older (60-74 vs ≥75) group. The significant hazard ratio of reoperation for <40 versus ≥75 years of age was 12, <40 versus 60 to 74 was 4, 40 to 59 versus 60 to 74 was 3, and 40 to 59 versus ≥75 was 9 (P ≤ .01). The 10- and 15-year survival in the entire cohort was 53% and 29%, respectively. CONCLUSIONS: The stentless aortic valve provides satisfactory durability as a conduit for aortic valve/root replacement for patients who prefer a bioprosthesis. However it should be judiciously considered for patients younger than 60 years because of an increased incidence of reoperation for structural valve deterioration.
BACKGROUND: The longevity of a stentless valve in a younger population (20-60 years old) is unknown. METHODS: From 1992 to 2015, 1947 patients underwent aortic valve/root replacement for aortic stenosis, insufficiency, root aneurysm, or aortic dissection with stentless bioprostheses (median size, 26 mm). At operation 105 patients were <40 years old, 528 were 40 to 59, 860 were 60 to 74, and 454 were ≥75 years. The data were obtained through chart review, administered surveys, and the National Death Index. RESULTS: The 30-day mortality rate was 2.6%. During follow-up 807 patients (41%) died before reoperation, 993 (51%) were alive without reoperations because of deterioration, and 113 patients (5.8%) underwent reoperation for structural valve deterioration. After adjusting death and reoperation for non-structural valve deterioration causes as competing risks, the cumulative incidence of reoperation was significantly different between the younger groups (<40, 40-59) and the older groups (60-74, ≥75; P < .0001) but not inside the younger (<40 vs 40-59) or older (60-74 vs ≥75) group. The significant hazard ratio of reoperation for <40 versus ≥75 years of age was 12, <40 versus 60 to 74 was 4, 40 to 59 versus 60 to 74 was 3, and 40 to 59 versus ≥75 was 9 (P ≤ .01). The 10- and 15-year survival in the entire cohort was 53% and 29%, respectively. CONCLUSIONS: The stentless aortic valve provides satisfactory durability as a conduit for aortic valve/root replacement for patients who prefer a bioprosthesis. However it should be judiciously considered for patients younger than 60 years because of an increased incidence of reoperation for structural valve deterioration.
Authors: K Hammermeister; G K Sethi; W G Henderson; F L Grover; C Oprian; S H Rahimtoola Journal: J Am Coll Cardiol Date: 2000-10 Impact factor: 24.094
Authors: Nicolas Amabile; Olivier M Bical; Alexandre Azmoun; Ramzi Ramadan; Remi Nottin; Philippe H Deleuze Journal: J Thorac Cardiovasc Surg Date: 2014-02-26 Impact factor: 5.209
Authors: Bo Yang; Himanshu J Patel; Elizabeth L Norton; Christina Debenedictus; Linda Farhat; Xiaoting Wu; Kevin He; Whitney E Hornsby; Donald S Likosky; G Michael Deeb Journal: Ann Thorac Surg Date: 2018-04-03 Impact factor: 4.330
Authors: Juergen Ennker; Markus Meilwes; Joern Pons-Kuehnemann; Bernd Niemann; Philippe Grieshaber; Ina C Ennker; Andreas Boening Journal: Asian Cardiovasc Thorac Ann Date: 2016-10-18
Authors: Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas Journal: Circulation Date: 2014-03-03 Impact factor: 29.690
Authors: Andrew G Sherrah; Richmond W Jeremy; Rajesh Puranik; Paul G Bannon; P Nicholas Hendel; Matthew S Bayfield; Michael K Wilson; Peter W Brady; David Marshman; Manu N Mathur; R John Brereton; James R Edwards; Robert G Stuklis; Michael Worthington; Michael P Vallely Journal: Heart Lung Circ Date: 2015-06-10 Impact factor: 2.975
Authors: Adriaan W Schneider; Hein Putter; Mark G Hazekamp; Eduard R Holman; Eline F Bruggemans; Michel I M Versteegh; Martin J Schalij; Rens R B Varkevisser; Robert J M Klautz; Jerry Braun Journal: Eur J Cardiothorac Surg Date: 2018-06-01 Impact factor: 4.191
Authors: Jeffrey Clemence; Juan Caceres; Tom Ren; Xiaoting Wu; Karen M Kim; Himanshu J Patel; G Michael Deeb; Bo Yang Journal: J Thorac Cardiovasc Surg Date: 2020-08-26 Impact factor: 6.439